医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biological Industries Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

2016年05月23日 PM09:45
このエントリーをはてなブックマークに追加


 

KIBBUTZ BEIT HAEMEK, Israel & CROMWELL, Conn.

Biological Industries (“BI”; www.bioind.com), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, is participating and making a poster presentation at ISCT 2016, the annual meeting of the International Society for Cellular Therapy, 25-28 May, in Singapore.

The poster presentation, “A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources,” will be presented by BI’s R&D Product Manager, Mira Genser-Nir, Ph.D.

Presentation Details

  • Abstract Number: 205
  • Presentation Title: A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources
  • The poster will be available for the duration of the conference

“Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells that can be isolated from various tissues as well as generated in vitro from hESCs and iPS cells,” observed Dr. Genser-Nir. “In order for hMSCs to become the cells of choice for use in regenerative medicine and drug screening, the culture conditions must be improved and differentiation potential is required. We feel that this paper represents a big step toward addressing these issues.”

BI will also have a booth at the conference, #C07-C09.

More information on ISCT 2016 is available at www.isct2016.com.

About Biological Industries

BIOLOGICAL INDUSTRIES (BI) develops, manufactures, and supplies life science products to universities, government research, healthcare institutions, and the biopharmaceutical industry. For over 30 years, BI has been working alongside some of the world’s leading academic researchers and institutes in the development of cell culture media, stem cell reagents, and molecular biology tools. BI also offers custom media development and manufacturing services through its ISO 13485:2003 certified cGMP facilities. BI currently supplies products to researchers and clinicians in over 40 countries with products currently in clinical trials. BI is leveraging their industry-leading experience in cell culture media and pluripotent stem cell technology to help facilitate breakthroughs in stem cell research worldwide. BI is committed to a Culture of Excellence by providing the highest quality reagents and cost-effective, innovative products and services tailored to a customer’s specific needs.

To receive ongoing BI communications, please join our email list or connect with the company on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160523005816/en/

CONTACT

Media:
Gotham
Communications
for Biological Industries
Bill
Douglass
, +1-646-504-0890
bill@gothamcomm.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究